

# A TEAM OF SPECIALISTS PROVIDING UNRIVALLED SOURCE OF STRATEGIC INTELLIGENCE FOR THE RADIATION HEALTHCARE



**Vincent BRECHIN**

PhD, Medical scientist  
Senior consultant, NucAdvisor  
vincent.brechin@nucadvisor.com  
Phone: +33 (0)1 40 88 41 43



**Paul-Emmanuel GOETHALS**

MBA  
Expert  
peg@medraysintell.com  
Phone: +32 491 080 968



**Nicolas MARIO**

MSc, Nuclear engineer  
Senior consultant, NucAdvisor  
nicolas.mario@nucadvisor.com  
Phone: +33 (0)1 40 88 41 46



**Richard ZIMMERMANN**

PhD  
Expert

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiopharmaceuticals, cyclotrons, proton therapy and brachytherapy.

MEDraysintell was created in 2013 by **Paul-Emmanuel Goethals** and **Richard Zimmermann**. In 2024, **Nicolas Mario** and **Vincent Bréchin**, who have respective nuclear engineering and medical science backgrounds, supported the integration of the MEDraysintell business into NucAdvisor ([www.nucadvisor.com](http://www.nucadvisor.com)). NucAdvisor is a high-level consulting company specialized into nuclear applications, covering energy, research, and healthcare applications, with a dedicated team of about 30 in-house experts and specialists. The team also relies on an external network of specialists.


MEDraysintell offers the **most comprehensive set of reports and directories, with more than 5000 pages of unrivalled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.** We offer client-specific intelligence in the field of radiation healthcare, with the utmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them better understand the markets and competitive environment, the potential for mergers and acquisitions (M&A) and technology development. We have repeatedly satisfied clients in the fields of medical radiation, conventional pharmaceutical and radiopharmaceutical industries, investment banking and institutional investments, large international consulting firms, public institutions, and university research laboratories.



## NUCLEAR MEDICINE REPORT & DIRECTORY 2024

A set of three reports (nearly 4,030 pages) aiming to provide a comprehensive and exhaustive review of the worldwide nuclear medicine landscape, through a description of about 1160 products, including 140 radionuclides used for industrial and R&D purposes, together with a comprehensive profile of 425 companies active in nuclear medicine, radiopharmaceutical development production and sale.




To obtain a detailed table of contents and sample pages, send an e-mail with your contact details at [contact.healthcare@nucadvisor.com](mailto:contact.healthcare@nucadvisor.com)

## CYCLOTRONS


A 450-page evaluation report and directory identifying some 1,500 cyclotrons worldwide dedicated to the production of medical radionuclides (for nuclear medicine - radiopharmaceuticals), with an exhaustive profile of the 17 companies active in this market.

Last publication in March 2020



## LATEST EVOLUTIONS ON THE NUCLEAR MEDICINE MARKET


The global market for nuclear medicine reached US\$ 9.3 billion in 2023 growing by 29% compared to 2022. The therapeutic radiopharmaceuticals accounted for 24% of the world market in 2023, versus 6% in 2013. Several new radiotherapeutics with strong revenues' potential to reach the market before 2029. The concept of radiotheranostics is now in all minds. <sup>177</sup>Lu labeled drugs will mainly develop in parallel to their equivalent <sup>18</sup>F-, <sup>68</sup>Ga- or <sup>89</sup>Zr-labeled tracers (radiotheranostic approach). The first α-radiotherapeutics labelled with <sup>225</sup>Ac or <sup>212</sup>Pb could possibly reach the market before the end of the decade, opening new treatment possibilities for cancer patients. There are multiple openings for larger corporations or investors to fund these developments and potentially collaborate through M&A.



## PROTON THERAPY

This seventh edition of the renowned World Proton Therapy report features in a 380-page document a comprehensive review of the world market dynamics with an analysis of both past evolutions and future trends to the year 2030, and a detailed profile of 36 promoters, manufacturers or developers of proton and carbon therapy equipment with a directory of all PT facilities already active or expected to become operational by 2025.

Last publication in March 2021



## BRACHYTHERAPY

This second edition of the most comprehensive evaluation report and directory of the brachytherapy industry providing in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.

Last publication in March 2016





# CONSULTING SERVICES

## SUPPORT TO THE INDUSTRY

Our specialists developed privileged links with the industry, supporting projects from feasibility to safe commercial operation around the entire RI/RP supply chain. Services offered include:

- Market studies, business cases, optioneering studies.
- High-level strategic support for shaping industrial strategy, manufacturing tools development or investment decision.
- Owner engineer support services for manufacturing installations (research centres, research reactors, laboratories), from design to operation.



## SUPPORT TO INVESTORS

We support investment funds, private investors, major international consulting companies for performing due diligence projects on players of the radiopharmaceutical and radionuclide supply chains or for specific investment in manufacturing infrastructures. Our team can provide tailor-made technical and investment support services, such as:

- Strategic analysis (stakeholders' involvement, competitive landscape, SWOT analysis, roadmaps).
- Market studies, business model definition, optioneering studies.
- Advising on Mergers & Acquisitions, financial and technical due diligence.



## SUPPORT TO PUBLIC INSTITUTIONS

Our expert knowledge, combined with robust experience in collaborating with European medical and industrial professional organizations, enables us to serve public interests, including:

- Supply chain mapping, current demand and projections, optioneering studies.
- Organisation and technical coordination of scientific conferences and events.
- Compliance assessments and support to application of European or national regulations on ionising medical applications.



Visit us at  
[www.medraysintell.com](http://www.medraysintell.com)

### Contact

Nicolas Mario | [nicolas.mario@nucadvisor.com](mailto:nicolas.mario@nucadvisor.com)  
Vincent Brechin | [vincent.brechin@nucadvisor.com](mailto:vincent.brechin@nucadvisor.com)  
Paul-Emmanuel Goethals | [peg@medraysintell.com](mailto:peg@medraysintell.com)